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Abstract
Colorectal cancer is one of the most common cancers in developed nations and is the result of both environmental and
genetic factors. Many of the genetic lesions observed in colorectal cancer alter expression of homeobox genes, which
encode homeodomain transcription factors. The MEIS1 homeobox gene is known to be involved in several hematological
malignancies and solid tumors and recent evidence suggests that expression of the MEIS1 transcript is altered in colorectal
cancer. Despite this potential connection, little is known about the role of the gene in the intestines. We probed murine
gastrointestinal tissue samples with an N-terminal Meis1 antibody, revealing expression of two previously described
isoforms, as well as two novel Meis1 products. A 32 kD Meis1 product was expressed in the nuclei of non-epithelial cells in
the stomach and colon, while a 27 kD product was expressed in the cytoplasm of epithelial cells in the proximal colon. Our
data suggest that the 27 kD and 32 kD Meis1 proteins are both forms of the Meis1d protein, a homeodomain-less isoform
whose transcript was previously identified in cDNA screens. Both the MEIS1D transcript and protein were expressed in
human colon mucosa. Expression of the MEIS1D protein was downregulated in 83% (10/12) of primary colorectal cancer
samples compared to matched normal mucosa, indicating that MEIS1D is a biomarker of colorectal tumorigenesis. The
decreased expression of MEIS1D in colon tumors also suggests that this conserved homeodomain-less isoform may act as a
tumor suppressor in human colorectal cancer.
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Introduction
Colorectal cancer accounts for approximately 10% of both
cancer diagnoses and mortalities in the United States (www.
cancer.org). The mortality rate has decreased in the previous two
decades, primarily reflecting higher levels of compliance with
recommended colonoscopy screenings as well as the improved
efficacy of therapeutic options [1]; however, colorectal cancer still
has the second highest mortality incidence in the United States,
trailing only lung cancer. Like many types of cancer, colorectal
cancer has both environmental and genetic components [2,3,4].
Both sporadic and hereditary forms of the disease are associated
with an accumulation of multiple genetic lesions [5,6], which can
result in decreased levels of apoptosis [7], loss of cell cycle
regulation [8], and constitutive activation of the WNT signaling
pathway [9]. As regulators of downstream transcriptional
activation, transcription factors are frequently dysregulated in
colorectal cancer [10,11].
Homeobox genes encode proteins with DNA-binding domains
known as homeodomains. These homeodomain proteins act as
transcription factors, binding promoter regions and activating
transcription [12]. HOX gene family members are the prototypical
homeobox genes. HOX genes are involved in embryonic
segmentation and patterning as well as the development of
numerous organ systems, including the gastrointestinal tract [12].
Developmental genes are often ectopically expressed during
carcinogenesis [13] and several HOX genes have been linked to
colorectal cancer. HOXB6, HOXB8, HOXC8, HOXC9, and
HOXD13 are overexpressed in both colorectal cancer cell lines
and primary colon tumors [14,15,16]. HOXB13, however, is
normally expressed in colonic mucosa but is downregulated in
tumor tissue [10]. Deregulation of non-HOX homeobox genes has
also been observed in colorectal carcinomas. CDX1 and CDX2 are
downregulated during colorectal carcinogenesis [17,18], while
aberrant PROX1 expression in the colon results in increased
dysplasia [19].
Homeodomain transcription factors often bind promoter
regions as either homodimeric or heterodimeric complexes
[20]. This dimerization provides increased specificity of tran-
scriptional activation [21]. The MEIS1 homeodomain protein is
a known binding partner of several other homeodomain
proteins, including HOXA7, HOXA9, and PBX1 [22]. MEIS1
plays a role in the normal development of the hematopoietic
lineage and is overexpressed in a subset of acute myeloid
leukemias [23]. Increased MEIS1 expression has also been
observed in neuroblastomas and the expression level of the
MEIS1 transcript is a prognostic indicator in breast cancer [24].
Downregulation of total MEIS1 transcript was observed in
colorectal adenomas, suggesting a role for MEIS1 in intestinal
tumorigenesis [25].
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cancer, we examined the status of Meis1 in the colon. In this study,
we describe two novel Meis1 products expressed in the murine
gastrointestinal tract. These two proteins are expressed in different
cell types and subcellular compartments. Both proteins are
translated from the Meis1d transcript, a homeodomain-less splice
variant of Meis1. MEIS1D, the human homolog of Meis1d, was
identified in normal human colon tissue at both the mRNA and
protein level. Furthermore, we observe the downregulation of
MEIS1D expression in human colorectal cancers. These data
suggest that MEIS1D is a novel suppressor of colorectal
tumorigenesis and a potential therapeutic target for colon cancer.
Materials and Methods
Mouse colony
C57BL/6J (B6) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). Mice were maintained in the
AALAC-accredited TJU animal facility. This study was carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol, 343C, was approved by the
Institutional Animal Care and Use Committee of Thomas
Jefferson University, permit number A3085-01.
Retroviral Infection
Hct116 cells were obtained from the American Type Culture
Collection (Cat. No. CCL-247), where the identity of the cell line
was confirmed by STR analysis. MSCV-Meis1d and MSCV-Neo
plasmids were transfected into Phoenix cells using the Profection
Calcium Phosphate kit (Promega, Madison, WI). Cells were
incubated at 37uC for 24 hours to produce viral media. Viral
media was added to Hct116 cells in six well plates and spun at
1,800 rpm for 45 minutes. The cells were then incubated at 32uC
for 3 hours, the viral media was removed, and new viral media
was added. The cells were spun again at 1,800 rpm for 45 minutes
and incubated at 32uC for 3 more hours. Viral media was replaced
with DMEM and the cells were moved to 37uC for 48–72 hours to
allow translation of the inserted sequence.
Western blot analysis
B6 mice at 120 days of age were euthanized by CO2
asphyxiation followed by cervical dislocation. Tissue and cell
samples were washed in 16PBS and homogenized in lysis buffer
(50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 10%
glycerol; 1% Triton-X-100) with protease inhibitors (Roche
Applied Science, Indianapolis, IN). Protein concentration was
quantified using Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA). 20 mg of each sample was separated by SDS-PAGE
(10% acrylamide) and transferred to nitrocellulose membranes.
Membranes were blocked with 5% nonfat dry milk in 16TBST
(20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.05% Tween 20).
Primary antibodies were used overnight at 4uC: Meis1-N; Meis1d-
C; Gapdh (Abcam, Cambridge, MA); actin, histone H1, and
cytokeratin 18 (Santa Cruz Biotechnology, Santa Cruz, CA).
Horseradish peroxidase-conjugated secondary antibody (Vector
Laboratories, Berlingame, CA) was used at a 1:2500 dilution for
1 hour at room temperature. Proteins were visualized using
SuperSignal chemiluminescent substrate (Thermo Scientific,
Rockford, IL).
Subcellular fractionation
Tissue and cell samples were washed in16PBS and homogenized
in lysis buffer (10 mM Tris-HCl, pH 7.4; 5 mM MgCl2;1m M
DTT; 1 mM PMSF) with protease inhibitors (Roche Applied
Science, Indianapolis, IN). Lysates were then passed through a
25Kg needle and centrifuged at 6006ga t4 uC for 10 min. The
supernatant was labeled the cytoplasmic fraction. The pellet was
resuspended in lysis buffer and labeled the nuclear fraction.
Epithelial cell isolation
Proximal and distal colon samples were cut into 1 mm wide
strips. The samples were incubated in 16PBS with 0.15% DTT
for 30 min at room temperature with constant agitation by stir bar
to remove mucus. Mucosal strips and stir bar were washed in 16
PBS and then incubated in 16 PBS with 1 mM EDTA, pH 7.2
stirring for 60 min at room temperature to remove epithelial cells.
The EDTA solution was collected and centrifuged at 4706g for
5 min. Remaining tissue was incubated in the EDTA solution to
remove residual epithelial cells and then homogenized in lysis
buffer as described above. The epithelial pellet was resuspended in
RPMI 1640 and incubated with collagenase (Sigma-Aldrich, St.
Louis, MO) at 50 units/mL for 30 min at 37uC, vortexing gently
every five minutes. Samples were centrifuged at 2006g for 5 min.
The pellet was resuspended in 16 PBS, centrifuged again, and
resuspended in RPMI. The RPMI cell suspension was overlaid on
a 50% Percoll/PBS mixture. The Percoll gradient was centrifuged
at 4706g for 20 min. Epithelial cells were taken from the top of
the gradient, diluted with RPMI, and centrifuged at 8306g for
5 min. The cell pellet was resuspended in RPMI and centrifuged
again at 4706g for 5 min. The final cell pellet was homogenized in
western blot lysis buffer using a 25Kg needle.
RT-PCR
Tissue samples were homogenized in 1 mL TRI Reagent
Solution (Ambion, Inc, Austin, TX) and centrifuged at 12,0006g
for 15 min at 4uC. 200 mL chloroform were added. The samples
were mixed for 15 sec, incubated at room temperature for 3 min,
and centrifuged at 12,0006g for 20 min at 4uC. The top layer was
mixed with 500 mL of 2-propanol, incubated at room temperature
for 10 min, and centrifuged at 12,0006g for 20 min at 4uC. The
RNA pellet was washed with 75% ethanol and centrifuged at
7,5006g for 5 min. The RNA was then air dried and resuspended
in DEPC-treated water. SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA) was used to generate cDNA. All Meis1
transcripts were amplified in murine samples, while MEIS1D-
specific primers were used in human samples.
Immunohistochemistry
Tissues were fixed in Formalde-Fresh 10% buffered formalin
solution (Fisher Scientific) overnight at 4uC and stored in 70%
EtOH. Fixed tissues were embedded in paraffin and tissues were
cut and mounted on glass slides by the KCC Translational
Research Core Facility. Tissues were deparaffinized using citrate
buffer, pH 6.0 (Vector Laboratories, Berlingame, CA) and stained
with Meis1-N antibody overnight at 4uC. Anti-rabbit secondary
antibody (Vector Laboratories, Burlingame, CA) was used at a
1:200 dilution for 1 hour at 37uC followed by ABC Linker Kit
(Vector Laboratories, Berlingame, CA) for 30 min at 37uC.
Samples were developed using the DAB Peroxidase Substrate Kit
(Vector Laboratories, Burlingame, CA). Staining was visualized on
a Nikon Eclipse E600 microscope at either 46 or 206
magnification.
Ethics
The patients were consented using a written surgical consent
form which states the waste from surgery would be used for
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Jefferson University Hospital. The Thomas Jefferson University
Institutional Review Board (IRB) exempted this study from review
because they deemed that the study did not constitute human
subjects research and waived the need for consent due the fact that
the samples received were coded to remove identification.
Results
Two novel Meis1 isoforms are present in the murine
gastrointestinal tract
Although downregulation of MEIS1 in human colorectal cancer
has recently been observed, the role of the gene in gastrointestinal
(GI) homeostasis and tumorigenesis is poorly understood. To
determine the expression of murine Meis1 isoforms in the GI tract,
a western blot was performed on C57BL/6J (B6) GI lysates using a
polyclonal antibody targeted to the N-terminus of Meis1 (Meis1-
N). Products of 43 kD and 51 kD were observed in most samples
(Figure 1a). These molecular weights correspond with the known
sizes of two previously described isoforms, Meis1a and Meis1b,
respectively. Two additional bands were observed in some of the
samples: a ,32 kD protein present in the stomach and colon and
a ,27 kD protein expressed in the proximal colon and cecum
(Figure 1a). The ,27 kD product is the same as the predicted
weight for Meis1d, another Meis1 isoform. The transcript for
Meis1d was previously identified during screens of murine cDNA
[26,27]. The isoform lacks all of exon 8, resulting in a premature
stop codon in exon 9 and a theoretical truncated protein product
(Figure 1c, d). The existence of an in vivo protein product, however,
has never been confirmed.
Meis1d, a truncated Meis1 isoform, is expressed in the
murine cecum and proximal colon
If the 27 kD Meis1 product is Meis1d, then the Meis1d
transcript should be detectable in the proximal colon. To
determine if the Meis1d transcript is present, Meis1 splice variants
were amplified from B6 proximal colon cDNA samples using RT-
PCR. Primers were designed to amplify across exon 8,
distinguishing Meis1d from the full length isoforms, Meis1a and
Meis1b. The PCR reaction amplified products of approximately
758 and 904 bp in length, the predicted size of products from
Meis1d and Meis1a/b transcripts (Figure 1b). The size difference
between the two products corresponds with the known length of
exon 8 (146 bp), suggesting that the smaller product is lacking that
exon. Extraction and sequencing of the smaller PCR product
confirmed the absence of exon 8 from the PCR product (data not
shown), demonstrating the presence of the Meis1d transcript in the
murine proximal colon.
Removal of exon 8 from the Meis1d transcript causes a
frameshift in exon 9. The result of this frameshift is the production
of truncated protein product with five novel amino acids on the C-
terminus (Figure 1d). Since these residues are not present on full
length Meis1 isoforms, a custom antibody targeting the unique
epitope (Meis1d-C) was generated. To determine if the custom
antibody recognizes the ,27 kD Meis1 product, colon lysates
from B6 mice were probed with the Meis1d-C and Meis1-N
antibodies. Proximal colon and distal colon lysates were used as
positive and negative controls, respectively. As expected, the
Meis1-N antibody picked up the previously identified ,27 kD
band in the proximal colon, but not the distal colon (Figure 2a).
The same expression pattern was observed in the samples probed
with the Meis1d-C antibody, demonstrating that the Meis1d-C
antibody detects the ,27 kD Meis1 product and indicating that
the product is Meis1d (Figure 2a). To determine the spatial
expression pattern of the Meis1d protein, lysates from a panel of
B6 organs were probed with the Meis1d-C antibody. Meis1d
expression was limited to the cecum and proximal colon
(Figure 2b, c).
Posttranslational modification of Meis1d correlates with
subcellular localization
Homeodomain-less isoforms of other homeodomain proteins
have been shown to function through two mechanisms. The
homeodomain-less proteins can sequester full length isoforms in
the cytoplasm through dominant negative interactions. Homeo-
domain-less isoforms can also act as nuclear binding partners for
other transcription factors, altering the activation of downstream
target genes. Therefore, the subcellular localization of Meis1d may
indicate the functional role of the isoform in the colon. To
determine the subcellular localization of Meis1d, B6 proximal
colon lysates were separated into nuclear and cytoplasmic fractions
and probed with Meis1-N antibody. As expected, full length Meis1
Figure 1. Novel Meis1 isoforms are present in the murine gastrointestinal tract. A) Western blot analysis of B6 gastrointestinal lysates using
the Meis1-N antibody. Gapdh was used as a loading control. PSI, MSI, and DSI indicate lysates from the proximal, middle, and distal small intestines,
respectively. PC and DC indicate lysates from the proximal and distal colons. B) Amplification of Meis1 isoforms from B6 proximal colon cDNA using
RT-PCR. Diagrams of the C) transcripts and D) products of Meis1a, Meis1b, and Meis1d isoforms are included. The locations of the two Meinox
domains (M1 and M2) and the homeodomain (HD) are labeled.
doi:10.1371/journal.pone.0023665.g001
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product was also present in the nucleus. The 27 kD Meis1d
protein, however, was only observed in the cytoplasmic fraction
(Figure 3a). These localization data indicate that Meis1d is not
acting as a transcription factor or sequestering full length Meis1
outside the nucleus, suggesting that the isoform has novel
cytoplasmic functions.
To study the effects of Meis1d expression in vitro, the open
reading frame (ORF) of Meis1d was retrovirally infected into the
HCT116 colon cancer cell line. Western blot analysis of cell lysates
revealed the presence of a 32 kD protein that was detected by the
Meis1-N antibody, but not the Meis1d-C antibody (Figure 3b).
This in vitro Meis1d product is ,5 kD larger than the expected
27 kD protein predicted by the Meis1d transcript and observed in
vivo (Figure 3b). However, the molecular weight matches the novel
32 kD Meis1 isoform previously observed in B6 stomach and
colon lysates (Figure 1a). The molecular weight of in vitro Meis1d
was confirmed in both murine 3T3 and simian Cos-1 cells,
indicating that the increased size is not cell line specific (data not
shown). Posttranslational modification of the in vitro Meis1d
product may be the cause of the increased molecular weight, as
well as the inability of the Meis1d-C antibody to detect the protein.
Unlike the 27 kD Meis1d product, the 32 kD Meis1 isoform is
localized to the nucleus in the proximal colon. To determine if in
vitro Meis1d is also localized to the nucleus, HCT116 cells
expressing Meis1d were fractionated. The 32 kD in vitro Meis1d
product was present in the nuclear lysates, recapitulating the in vivo
subcellular localization of the novel 32 kD isoform (Figure 3c).
These data suggest that both the 27 kD and 32 kD Meis1 isoforms
observed in the murine GI tract are translated from the Meis1d
transcript. The cytoplasmic form (Meis1d27) is the predicted
molecular weight of Meis1d, while the nuclear form (Meis1d32)i s
larger, most likely due to posttranslational modification.
Figure 2. The Meis1d protein is present in the murine colon.
A) Western blot analysis of B6 proximal and distal colon lysates with the
Meis1-N and Meis1d-C antibodies. The positions of Meis1, Meis1b, and
the two novel Meis1 products are labeled. B) and C) Lysates from a
panel of B6 organs were probed with the Meis1d-C antibody. Gapdh
was used as a loading control.
doi:10.1371/journal.pone.0023665.g002
Figure 3. Posttranslational modification of Meis1d correlates
with subcellular localization. A) B6 proximal colon samples were
separated into nuclear and cytoplasmic fractions and probed with the
Meis1-N antibody. Histone H1 was used to confirm the subcellular
fractionation. B) Western blot analysis of B6 proximal colon and Hct116
cells expressing the Meis1d ORF using the Meis1-N antibody. C) Hct116
cells were retrovirally infected with the Meis1d ORF or an empty MSCV
vector. Cells were taken 72 hours post-infection, fractionated, and
probed with the Meis1-N antibody. The positions of Meis1a, nuclear
Meis1d (Meis1d32), and cytoplasmic Meis1d (Meis1d27) are labeled
where applicable.
doi:10.1371/journal.pone.0023665.g003
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the colon
The colon consists of a single layer of epithelial cells covering
the lamina propria and several muscle layers. Colon cancer is
derived from stem cells located in the epithelial layer [28]. To
determine if either Meis1d27 or Meis1d32 are expressed in the
colonic epithelium, epithelial cells were isolated from B6 proximal
and distal colon samples. Lysates from the isolated epithelial cells
and lamina propria/muscle layers were probed with Meis1-N
antibody. The Meis1d27 protein was expressed exclusively in the
epithelial cells of the proximal colon (Figure 4a). Meis1d32,
however, was expressed in the lamina propria/muscle layers from
both the proximal and distal colon (Figure 4a). The full length
Meis1 isoforms, Meis1a and Meis1b, were also present in only the
lamina propria/muscle samples (Figure 4a). These data indicate
that the nuclear and cytoplasmic forms of Meis1d are not present
in the same cell populations in the murine colon. Furthermore,
Meis1d27 is expressed in colonic epithelial cells in the absence of
full length Meis1. To further confirm the epithelial cell expression
of Meis1d27, B6 colon samples were stained with Meis1-N
antibody. Strong cytoplasmic staining was observed in the
epithelium of the proximal colon, but not the distal colon
(Figure 4b). This expression pattern recapitulates the expression
of Meis1d27, again suggesting that Meis1d27 is present in the
epithelial cells of the proximal colon.
Expression of the MEIS1D protein is downregulated in
human colorectal cancers
Meis1 is highly conserved in eukaryotes and removal of exon 8
from the human MEIS1 mRNA would encode a predicted
protein product with 99% homology to murine Meis1d. Based on
the evolutionary conservation of Meis1, we attempted to
characterize the expression of MEIS1D in the human colon. A
western blot was performed on human colon lysates using the
Meis1-N antibody. A band the predicted size of MEIS1D27 was
observed in human colon samples (Figure 5b). To confirm the
expression of the MEIS1D transcript, RT-PCR was performed
on human colon cDNA (Figure 5a). A 758 bp band was
amplified, indicating that MEIS1D mRNA is transcribed in the
human colon.
Expression of full length MEIS1 is known to be dysregulated
in several solid tumors [29,30]. To determine the status of
MEIS1 in colorectal cancer, western blots were performed on
matched normal colon and primary colorectal tumor lysates
using the Meis1-N antibody. MEIS1A and MEIS1B were
expressed in both tumor and normal samples, while MEIS1D32
was not present in either set of samples (data not shown).
However, 83% (10/12) of normal colon mucosa samples
expressed detectable levels of MEIS1D27 protein (Figure 5b).
Expression was reduced or completely lost in all matched tumor
samples from these patients (Figure 5b). The remaining two
Figure 4. Meis1d27 and Meis1d32 are expressed in different
cellular populations. A) B6 proximal and distal colon samples were
separated into epithelial and non-epithelial fractions. The non-epithelial
fractions consist of the lamina propria and muscle layers of the colon.
The fractions and whole cell lysates from both colon segments were
probed with the Meis1-N antibody. Cos-1 cells expressing Meis1d were
used to compare the in vitro and in vivo molecular weights of Meis1d32.
B) B6 proximal and distal colon samples were stained with Meis1-N
antibody. Staining was visualized at 206magnification.
doi:10.1371/journal.pone.0023665.g004
Figure 5. MEIS1D27 is downregulated in human colorectal
cancers. A) RT-PCR amplification of MEIS1D transcript from human
colon cDNA. B) Western blot analysis of lysates from human colorectal
tumors (T) and matched normal mucosa (N) using the Meis1-N
antibody. GAPDH was used as a loading control. Samples represent
all four sections of the human colon: ascending, transverse, descending,
and sigmoid.
doi:10.1371/journal.pone.0023665.g005
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normal mucosa and tumor tissue (Figure 5b). These in vivo data
indicate that MEIS1D27 expression is downregulated during
intestinal tumorigenesis.
Discussion
Alternative splicing is known to produce two Meis1 isoforms,
Meis1a and Meis1b, in both mice and humans. Both the Meis1a
and Meis1b proteins are full length, containing the two Meinox
domains involved in protein-protein interactions and the DNA-
binding homeodomain (Figure 2d). The protein products of these
splice variants differ in the C-terminus, due to the splicing out of
exon 12 from the Meis1b coding sequencing (Figure 2c, d).
Evidence suggests that the two similar isoforms may activate
transcription of different subsets of genes [31]. Screens of cDNA
libraries indicate that a large number of additional alternatively
spliced transcripts are produced from the Meis1 locus [26,27,32].
Unlike Meis1a and Meis1b, however, proteins for other Meis1
transcripts have not been observed in vivo. Therefore, it remains
unclear whether these transcripts are functionally relevant or
simply artifacts generated by incorrect alternative splicing.
In this paper, we have described two protein products of the
Meis1d splice variant, an isoform previously identified in cDNA
screens. The Meis1d transcript lacks exon 8, resulting in a
predicted 27 kD protein lacking the homeodomain (Figure 2c,
d). This 27 kD product was observed in the cytoplasm of proximal
colon epithelial cells (Figures 3a, 4a). A second, 32 kD Meis1d
product occurs in the nuclei of non-epithelial cells in the stomach
and colon (Figures 3a, 4a). The cytoplasmic and nuclear forms of
Meis1d have been named Meis1d27 and Meis1d32, respectively.
The larger molecular weight and nuclear localization of the
Meis1d32 protein are recapitulated in cells transfected with the
Meis1d ORF (Figure 3b). Expression of MEIS1D27 in human colon
samples was also observed, demonstrating evolutionary conserva-
tion of this novel isoform (Figure 5). Meis1d is only the third Meis1
isoform for which a translated protein product has been confirmed
and is also the first homeodomain-less Meis1 product observed in
either mice or human tissues.
Homeodomain-less isoforms have been described for many
homeobox genes, including several members of the Hox family.
Only a few of these isoforms, however, have been identified in
TALE superfamily genes, a group including Meis1. The loss of the
homeodomain prevents direct binding to DNA target sequences
and normal transcriptional activation. Homeodomain-less iso-
forms of TALE transcription factors, however, have been
previously shown to still regulate transcription through two
distinct mechanisms. The truncated isoforms can have dominant
negative effects, sequestering full length proteins in the cytoplasm
and preventing transcriptional activation of downstream targets
[33,34]. The homeodomain-less proteins can also interact
indirectly with DNA by binding other transcription factors to
form heterodimers. The presence of the truncated proteins alters
the DNA binding site of the protein complex, activating a distinct
subset of downstream targets [35].
Since homeodomain-less isoforms of related genes have distinct
mechanisms in the cytoplasm and nucleus, the subcellular
localizations of Meis1d and any potential binding partners may
suggest a cellular function. In the present study, Meis1d was
observed in either the nucleus or cytoplasm depending on cell
type. Meis1d27 is expressed in the cytoplasm of proximal colon
epithelial cells (Figures 3, 4). Full length isoforms are present in the
nuclear fraction of proximal colon lysates, indicating that Meis1d27
does not sequester other Meis1 isoforms in the cytoplasm
(Figures 3, 4). Further evidence indicates that Meis1d27 is not
expressed in the same cells as Meis1a or Meis1b, preventing any
kind of dominant negative interaction (Figure 4). The cytoplasmic
form of Meis1d may still bind other unknown transcription factors
and prevent nuclear localization. The isoform may also have a
novel homeodomain-independent function unrelated to transcrip-
tional activation.
The potential function of Meis1d27 is unclear because the data
does not fit either known mechanism of homeodomain-less TALE
proteins. The protein can not be acting as a dominant negative,
since it is not expressed in the same cells as other Meis1 isoforms.
Meis1d27 also can not be activating downstream transcription
inside the nucleus, because the protein is localized to the
cytoplasm. The nuclear form of Meis1d, however, may still fit
either of these mechanisms in the lamina propria or muscle
surrounding the colon. The nuclear localization of Meis1d32
means the protein could be acting as a binding partner for other
transcription factors. Meis1d32 still maintains the motifs required
for Pbx interaction and homodimerization [36]. These data
suggest that the truncated isoform could still function as a co-factor
with these other homeodomain proteins. The Meis1d32 protein
may also be acting as dominant negative isoform inside the
nucleus, preventing association between full length Meis1 proteins
and promoter regions in the DNA. Further dissection of the
lamina propria and the underlying muscle layer is necessary to
determine if Meis1d32 and any potential binding partners are
expressed in the same population of cells. Identification of
functional roles for both Meis1d32 and Meis1d27 will help explain
the relevance of Meis1 splicing in intestinal function and
homeostasis.
Despite the lack of a defined function, we have provided
evidence that MEIS1D27 is downregulated in primary colorectal
cancers compared to normal mucosa (Figure 5b). These data may
explain the downregulation of total MEIS1 transcript previously
observed in early colon adenomas [25]. Preliminary data also
suggests that MEIS1D27 is not expressed in the Hct116, LoVo, or
SW480 cell lines, which are derived from human colon cancers
(data not shown). Tumor suppressor genes are functionally
inactivated during tumor initiation and progression through
somatic mutations or loss of expression. These data suggest that
MEIS1D27 may act as a tumor suppressor in the colon. The loss of
MEIS1D27 during intestinal tumorigenesis, however, may also be
indicative of more global changes in the transcriptome of the
tumor cell. Alternative splicing is an essential mechanism for
generating the protein diversity necessary for cellular function.
Splicing provides both direct and indirect regulation of multiple
cancer-related pathways, including apoptosis, signal transduction,
and differentiation [37,38,39]. As with other regulatory mecha-
nisms, alterations in alternative splicing have been observed in
primary human cancers [40,41]. Transcriptome-wide changes are
often caused by aberrant expression of splicing factors, resulting in
simultaneous downregulation of tumor suppressive isoforms and
upregulation of oncogenic isoforms. Newer microarrays can map
the transcriptome with exon-level resolution, allowing analysis of
these changes in primary tumors. Despite these technological
advancements, there are still difficulties identifying causative links
between production of specific isoforms and tumorigenesis. Due to
the global changes in alternative splicing observed in cancer,
MEIS1D may be one of many splice variants whose expression
levels change during intestinal tumorigenesis. Future work will
need to determine if there is a causative role for MEIS1D27 in
colorectal cancer or if the loss of the cytoplasmic isoform is simply
a biomarker of colorectal cancer.
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